-

11:38:07 PM

KURA Stock News

KURA - Kura Oncology Inc

05/06/21 4:04 PM

Nasdaq : KURA

earnings

Kura Oncology Reports First Quarter 2021 Financial Results

– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window – – KOMET-001 trial amended to include Phase 1b expansion cohorts enriched with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients – – Data from

RHEA-AI

very positive

04/29/21 7:30 AM

Nasdaq : KURA

conferencesearnings

Kura Oncology to Report First Quarter 2021 Financial Results

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2021 financial results after the

RHEA-AI

neutral

03/22/21 4:08 PM

Nasdaq : KURA

clinical trial

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS compared with median PFS of 3.6 months on last prior therapy (p=0.0012) – – Safety profile consistent

RHEA-AI

very positive

02/24/21 7:20 AM

Nasdaq : KURA

earnings

Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results

– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a wide therapeutic window in dose escalation; protocol amendment to include genetically enriched Phase 1

RHEA-AI

positive

02/24/21 7:00 AM

Nasdaq : KURA

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been granted

RHEA-AI

positive

02/18/21 7:30 AM

Nasdaq : KURA

conferences

Kura Oncology to Participate in Four Upcoming Investor Conferences

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive officer

RHEA-AI

neutral

02/17/21 7:30 AM

Nasdaq : KURA

conferencesearnings

Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2020 financial

RHEA-AI

neutral

01/07/21 7:30 AM

Nasdaq : KURA

conferences

Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the

RHEA-AI

neutral

01/06/21 7:30 AM

Nasdaq : KURA

conferences

Kura Oncology to Present at J.P. Morgan Healthcare Conference

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 39 th Annual J.P. Morgan Healthcare

RHEA-AI

neutral

12/11/20 4:05 PM

Nasdaq : KURA

offering

Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offering

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 Next

KURA Data

Websitewww.kuraoncology.com
CeoTroy Wilson
Security nameKura Oncology Inc
Issue typecs
Sic code2834
Employees89
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address12730 High Bluff Drive, Suite 400
StateCalifornia
CitySan Diego
Zip92130
CountryUS
Phone18585008800

About Kura Oncology Inc

Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets; however, no molecular mechanism of action had been determined that could explain its clinical activity across a range of solid tumor and hematologic indications. Leveraging advances in next generation sequencing as well as emerging information about cancer genetics and tumor biology, the Company is seeking to identify those patients most likely to benefit from tipifarnib. In addition to Breakthrough Therapy Designation, tipifarnib has been granted Fast Track designation by the FDA for the treatment of patients with HRAS mutant HNSCC. In addition to HNSCC, tipifarnib has demonstrated encouraging clinical activity in a number of additional genetically defined tumor types. Kura has received multiple issued patents for tipifarnib, providing patent exclusivity in the U.S. and foreign countries. About Kura Oncology